Immunotherapy Patients Have Access To:

  • The Blood and Marrow Transplant Group of Georgia physician team. The physicians have completed post-hematology/oncology fellowship training in hematopoietic stem cell transplantation and have vast experience administrating immunotherapy agents for hematological malignancies.
  • Interdisciplinary Team that includes a dedicated health psychologist, social worker, clinical BMT Pharm D.’s, nutritional services, physical therapy, and chaplain services
  • State-of-the-Art facilities
  • Comprehensive quality management program
  • The Northside Hospital Blood and Marrow Transplant Program who has among the BEST BMT survival outcomes in United States
    • One of only two adult BMT programs in the country, and the only adult BMT Program in Georgia, to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic and unrelated donor transplants for the last 9 consecutive reporting cycles (2009-2017).1,2*
    • Only Core NCI BMT-CTN transplant center in the state of Georgia
  • NSH-Immunotherapy Program physicians will coordinate pre – post infusion care with your referring physician. Be assured treatment recommendations will be the most current and state-of-the-art.
  • Innovative clinical research trials so patients do not have to travel outside their community.
    • Participates in large national cooperative group clinical research trials and collaborates with academic-university institutions and the pharmaceutical industry
    • NCI- NCORP: Northside Hospital Cancer Institute and Lewis Cancer and Research Pavilion have collaborated with Georgia CORE to participate in NCORP. NCORP is a five-year NCI grant, which will provide cancer patients access to the latest NCI clinical trials in their local community.
  1. Reported outcome data from bethematch.org. This survival information includes only patients who received their first allogeneic transplant between January 1, 2013 and December 31, 2015 using unrelated or related donors, and who had reported follow-up.
  2. Final 2017 Transplant Center Specific Survival Report, December, 2017